結核菌の交叉耐性 (第2編)

概要

論文の詳細を見る
As reported in the previous paper, the cross-resistance of tubercle bacilli has to be studied in various phenotypes of the resistance. The number of phenotypes of M.tuberculosis (H37Rv) is shown in Table 1. Reports of in vitro cross-resistance studies on the ‘minor’ cross-resistance are shown in Table 2, and those on thh ‘major’ cross-resistance are shown in Table 3. Reports of cross-resistance studies on patient strains are shown in Table 4. The majority of the cross-resistance relationships in tubercle bacilli till now reported are concerned with aminoglycoside antibiotics. The studies concerned with other antituberculous drugs are the following two: PAS (para-aminosalicylate) and 4-acetyl-aminobenzaldehyde-thiosemicar bazone (Tb1); ethionamide and Tb1. There are two phenotypes in the PAS resistance. PAS-highlyresistant mutants are five times more resistant to Tb1 than parent susceptible organisms, but PAS-lowly-resistant mutants are susceptible to Tb1. Tb1-resistant mutants, both highly and lowly resistant ones, are susceptible to PAS. There are two phenotypes in the ethionamide resistance. Ethinamide-highly-resistant mutants are two times resistant to Tb1 than parent susceptible orga nisms. Ethionamide-lowly-resistant mutants remain susceptible to Tb1. Tb1-resistant mutants are susceptible to ethionamide. There is no report on the cross-resistance concerning with rifampicin, ethambutol, cycloserine and isoniazid.
日本結核病学会の論文

著者

束村道雄
国立療養所中部病院

結核菌の交叉耐性 (第2編)

スポンサーリンク

概要

著者

関連論文

スポンサーリンク